SEASTAR MEDICAL HOLDING CORP (ICU) Fundamental Analysis & Valuation
NASDAQ:ICU • US81256L3024
Current stock price
2.74 USD
-0.05 (-1.79%)
At close:
2.69 USD
-0.05 (-1.82%)
After Hours:
This ICU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ICU Profitability Analysis
1.1 Basic Checks
- In the past year ICU has reported negative net income.
- ICU had a negative operating cash flow in the past year.
- In the past 5 years ICU always reported negative net income.
- In the past 5 years ICU always reported negative operating cash flow.
1.2 Ratios
- ICU has a worse Return On Assets (-87.99%) than 77.78% of its industry peers.
- ICU's Return On Equity of -119.20% is on the low side compared to the rest of the industry. ICU is outperformed by 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.99% | ||
| ROE | -119.2% | ||
| ROIC | N/A |
ROA(3y)-587.39%
ROA(5y)-528.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ICU has a better Gross Margin (95.35%) than 98.94% of its industry peers.
- ICU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ICU Health Analysis
2.1 Basic Checks
- ICU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- ICU has an Altman-Z score of -14.03. This is a bad value and indicates that ICU is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of ICU (-14.03) is worse than 85.19% of its industry peers.
- There is no outstanding debt for ICU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.03 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- ICU has a Current Ratio of 3.66. This indicates that ICU is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.66, ICU is in the better half of the industry, outperforming 61.38% of the companies in the same industry.
- ICU has a Quick Ratio of 3.64. This indicates that ICU is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.64, ICU is in the better half of the industry, outperforming 69.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.66 | ||
| Quick Ratio | 3.64 |
3. ICU Growth Analysis
3.1 Past
- ICU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.33%, which is quite impressive.
EPS 1Y (TTM)89.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%526.87%
3.2 Future
- The Earnings Per Share is expected to grow by 30.11% on average over the next years. This is a very strong growth
- Based on estimates for the next years, ICU will show a very strong growth in Revenue. The Revenue will grow by 47.01% on average per year.
EPS Next Y59.54%
EPS Next 2Y30.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year54.99%
Revenue Next 2Y47.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
4. ICU Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ICU. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICU. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ICU's earnings are expected to grow with 30.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.11%
EPS Next 3YN/A
5. ICU Dividend Analysis
5.1 Amount
- ICU does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ICU Fundamentals: All Metrics, Ratios and Statistics
2.74
-0.05 (-1.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-25 2026-03-25/amc
Earnings (Next)05-12 2026-05-12
Inst Owners2.21%
Inst Owner Change-99.98%
Ins Owners2.53%
Ins Owner Change0.65%
Market Cap9.86M
Revenue(TTM)N/A
Net Income(TTM)-13.66M
Analysts80
Price Target9.18 (235.04%)
Short Float %6.65%
Short Ratio1.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.37%
Min EPS beat(2)14.19%
Max EPS beat(2)58.55%
EPS beat(4)3
Avg EPS beat(4)22.21%
Min EPS beat(4)-0.12%
Max EPS beat(4)58.55%
EPS beat(8)5
Avg EPS beat(8)3.4%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)19.9%
Min Revenue beat(2)-27.52%
Max Revenue beat(2)67.33%
Revenue beat(4)2
Avg Revenue beat(4)19.36%
Min Revenue beat(4)-55.78%
Max Revenue beat(4)93.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)800%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-863.64%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)-915.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)52.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)44.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.86 | ||
| P/tB | 0.86 | ||
| EV/EBITDA | N/A |
EPS(TTM)-8.3
EYN/A
EPS(NY)-3.36
Fwd EYN/A
FCF(TTM)-3.94
FCFYN/A
OCF(TTM)-3.94
OCFYN/A
SpS0.24
BVpS3.18
TBVpS3.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.99% | ||
| ROE | -119.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.35% | ||
| FCFM | N/A |
ROA(3y)-587.39%
ROA(5y)-528.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.66 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | -14.03 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.11%
EPS Next Y59.54%
EPS Next 2Y30.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%526.87%
Revenue Next Year54.99%
Revenue Next 2Y47.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.91%
OCF growth 3YN/A
OCF growth 5YN/A
SEASTAR MEDICAL HOLDING CORP / ICU Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for SEASTAR MEDICAL HOLDING CORP?
ChartMill assigns a fundamental rating of 3 / 10 to ICU.
What is the valuation status for ICU stock?
ChartMill assigns a valuation rating of 1 / 10 to SEASTAR MEDICAL HOLDING CORP (ICU). This can be considered as Overvalued.
What is the profitability of ICU stock?
SEASTAR MEDICAL HOLDING CORP (ICU) has a profitability rating of 1 / 10.
What is the expected EPS growth for SEASTAR MEDICAL HOLDING CORP (ICU) stock?
The Earnings per Share (EPS) of SEASTAR MEDICAL HOLDING CORP (ICU) is expected to grow by 59.54% in the next year.